‘Have tremendous vaccine experience,’ says Bharat Biotech physician amidst debate over efficacy data
Amid concerns over efficacy data for Covaxin, developed by Hyderabad-based Bharat Biotech, the company’s managing director, Krishna Ella, said its vaccine is safe and that the company is conducting trials on more than 12 countries other than India. “We are not a company without experience in vaccines. We have a tremendous experience in vaccines, “the ANI quoted Ella.
“We are touching 123 countries. We are the only company that has such extensive experience and such extensive publication in review journals, ”he also said.
“We are not just conducting clinical trials in India. We have conducted clinical trials in more than 12 countries, including the UK. We are conducting clinical trials in Pakistan, Nepal, Bangladesh and other countries. We are not just an Indian company, we are truly a global company, ”said Ella as well.
The government recently approved the use of emergency authorization for Covishield from Oxford-AstraZeneca and also for Covaxin from local development. Soon, experts searched for data on Covaxin.
Meanwhile, the director general of the Indian Council for Medical Research (ICMR), Dr. Balram Bhargava, said on Sunday that covaxin is based on an inactivated whole virus, which has the potential to attack mutated coronavirus strains, including UK variant, and that was one of the main reasons to run it. a conditional assent.
Speaking about the controversy surrounding the vaccine, Ella said: “Now that the vaccine is becoming politicized, I want to say very clearly that none of my family members are associated with any political party.”
“The approval of Covaxin for emergency use is a great step for innovation and development of novel products in India. It is a proud moment for the nation and a great milestone in India’s scientific capacity, a boost for the innovation ecosystem in India, ”said Ella as well.